Table 3.

Adjusted ORs, 95% CIs, and P values for pairwise genotype interactions and breast cancer case-control status

GeneCOMTCYP1A1*2CCYP1A2*1FCYP1B1*3CYP1B1*4CYP3A4SULT1A1*2SULT1A1*3SULT1E1
COMT14.27 (0.99-204.95) [0.051]1.45 (0.27-7.78) [0.665]2.05 (0.58-7.24) [0.263]2.63 (0.20-35.42) [0.465]0.61 (0.16-2.26) [0.457]1.24 (0.26-5.83) [0.784]0.55 (0.11-2.74) [0.463]1.44 (0.36-5.80) [0.607]
CYP1A1*2C0.82 (0.28-2.36) [0.706]1.65 (0.14-19.49) [0.692]1.74 (0.39-4.83) [0.470]2.45 (0.30-20.17) [0.405]0.54 (0.10-2.85) [0.472]0.78 (0.11-5.28) [0.800]1.72 (0.27-10.75) [0.564]0.60 (0.12-3.01) [0.536]
CYP1A2*1F1.37 (0.39-7.74) [0.628]2.79 (0.45-17.5) [0.272]1.49 (0.53-4.14) [0.449]1.18 (0.23-6.04) [0.836]0.24 (0.06-1.01) [0.052]0.40 (0.12-1.26) 0.1170.56 (0.18-1.75) [0.320]0.67 (0.23-1.96) [0.462]
CYP1B1*30.95 [0.46-1.94) [0.880]2.05 (0.63-6.66) [0.235]0.68 (0.24-1.94) [0.477]*0.61 (0.24-1.55) [0.301]0.73 (0.31-1.75) [0.483]1.74 (0.74-4.12) [0.206]0.46 (0.20-1.05) [0.066]
CYP1B1*40.59 (0.31-1.12) [0.104]0.96 (0.35-2.67) [0.940]0.57 (0.21-1.54) [0.267]*1.14 (0.30-4.24) [0.850]4.89 (1.06-22.48) [0.041]2.23 (0.50-9.95) [0.295]0.56 (0.12-2.67) [0.471]
CYP3A40.79 (0.25-2.45) [0.680]3.73 (0.37-37.34) [0.262]1.06 (0.24-4.77) [0.931]0.78 (0.31-1.94) [0.590]1.00 (0.38-2.66) [0.993]0.71 (0.23-2.23) [0.561]0.80 (0.27-2.44) [0.701]1.38 (0.47-4.01) [0.559]
SULT1A1*21.91 (0.97-3.74) [0.061]0.15 (0.05-0.42) [0.0004]0.50 (0.18-1.34) [0.167]0.87 (0.45-1.68) [0.673]0.71 (0.39-1.28) [0.251]1.99 (0.77-5.11) [0.153]*0.65 (0.26-1.64) [0.362]
SULT1A1*30.35 (0.03-8.72) [0.387]2.81 (0.29-27.49) [0.374]3.11 (0.47-20.82) [0.242]*0.88 (0.35-2.21) [0.785]
SULT1E11.20 (0.48-2.96) [0.695]1.81 (0.41-8.08) [0.440]6.95 (1.72-28.00) [0.0064]0.87 (0.40-1.87) [0.715]1.33 (0.63-2.83) [0.456]1.37 (0.47-4.00) [0.567]0.88 (0.42-1.83) [0.724]1.34 (0.19-9.33) [0.768]
  • NOTE: European American results are shown on the lower left triangle; African American results are shown on the upper right triangle. ORs were estimated from conditional logistic regression matched on age, and adjusted for the following variables: age at menarche, number of full-term pregnancies, age at menopause, duration of oral contraceptive use, body mass index, and existence of first-degree relative with breast cancer. Data are OR (95% CI) [P value].

  • * Interactions not computed for variants at the same locus.

  • Not estimable.